SEMA3G and central nervous system cancer: In the glioma samples, compared with the control samples, the expression levels of ACSL1, GCAT, SEMA3G, and WNT7B were increased, while those of BMP2, EN1, GRNDE, KLF10, PLOD3, SFRP2, TFPI, and TPX2 decreased.